Last reviewed · How we verify

NCT05199246: Exo-KGO1

Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders

Completed NA Last updated 16 April 2026
What this trial tests

NA trial testing Lower-limb powered dermoskeleton in Muscular Dystrophies in 50 participants. Completed in 22 April 2025.

Timeline
1 December 2021
Primary endpoint
22 April 2025
22 April 2025

Quick facts

Lead sponsorInstitut de Myologie, France
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment50
Start date1 December 2021
Primary completion22 April 2025
Estimated completion22 April 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Institut de Myologie, France — full company profile →

Who can join

Adults 18 to 70, any sex, with Muscular Dystrophies or Congenital Myopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of the current study are as follow: i) Evaluate the safety, usability, and acute efficiency of a programmable ambulation exoskeleton (KeeogoTM Dermoskeleton System, B-Temia Inc., Quebec, Canada) in patients with neuromuscular disorders, ii) Elaborate recommendations regarding usability criteria for safe and efficient use the device in patients with neuromuscular disorders (e.g. type and severity of patient's functional deficits), iii) generate necessary data to foresee a future study involving a home use of the device and assessment of long-term benefits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Muscular Dystrophies

Currently open trials in the same condition.

Other Institut de Myologie, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05199246.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing